



MRN: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

STANDARD REMICADE® (infliximab) PLAN OF TREATMENT FOR RHEUMATOLOGY

NOTE: Patient *may be ineligible* to receive infliximab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening symptoms of CHF, new-onset or deterioration neurological changes, and/or surgery.

1. Patient Name: _____ Height (inches): _____ Weight (lbs): _____

2. Allergies: _____

3. Diagnosis: * Please complete the 2nd and 3rd digits to complete the ICD-10 code for billing

- M05.____ Rheumatoid Arthritis with Rheumatoid factor M06.____ Rheumatoid Arthritis without Rheumatoid factor
L40.5____ Psoriatic Arthropathy M45.____ Ankylosing Spondylitis D86.0 Sarcoidosis of the Lung
Other ICD-10 Code: _____ Diagnosis description: _____

4. Pre-medications: None OR Administered 30 minutes prior to infusion as selected:

*Product information suggests premedication of antihistamines, acetaminophen, and/or corticosteroids.

Table with 2 columns: a) Acetaminophen (650mgs PO, 500mgs PO, 325mgs PO) and b) Diphenhydramine (25 mgs PO, 50mgs PO, 25 mgs IVP, 50mgs IVP or c) Alternate oral antihistamine to diphenhydramine (Cetirizine 10 mg, Loratadine 10 mg, Fexofenadine 60mgs or 180mgs) and d) Other (Methylprednisolone 40mgs IVP, 125mgs IVP or other ___mgs IVP; Famotidine 20mgs PO, 40mgs PO, 20mgs IVP, 40mgs IVP)

e) Pre-medicate with other: _____

CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion

Orders: Obtain weight each visit. Vital signs at baseline, every 30 minutes beginning with start of infusion, at completion, 30 minutes after completion for the first 3 treatments, and then may discharge when infusion is complete. Instruct patient/caregiver on medications and signs/symptoms of adverse reaction. Assess patient for response to therapy. Utilize existing central line for administration or initiate a peripheral IV with each infusion as needed. Sodium Chloride 0.9% flush 3-10 ml before, after, and as needed during the infusion. Follow infusion with Heparin 100 units/ml 1 – 5 ml per line type or to peripheral IV as required for multiple day treatments. Pump, tubing, 0.22 micron filter, and supplies needed to complete prescribed therapy. Pharmacist to perform clinical drug monitoring. If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES.

5. Dose: Remicade® (infliximab) 3 mg/kg per 250 ml Sodium Chloride 0.9% IV to infuse over at least 2 hours OR Other Dose: _____ mg or _____ mg/kg per 250 - 500 ml Sodium Chloride 0.9% IV

6. Frequency: Induction orders to be completed at 0 week, 2 week, and 6 weeks, and then every 8 weeks thereafter Orders every 8 weeks (maintenance). Special Orders: _____

Lab orders with infusions: _____

7. Physician's Signature: _____ / _____ Date: _____ No Stamp Signatures (Dispense as written) (Substitution permitted)

Printed Physician's Name with Credentials: _____

8. Fax updated supporting clinical MD notes with each order renewal or change in orders

Infusion order forms available at www.palmettoinfusion.com



MRN: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

Guidelines for Prescribing Remicade® (infliximab) for Rheumatology
(Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

Include signed and completed **Plan of Treatment**. (MD must complete sections 1-8)
(Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

Include patient demographic information and insurance information. (Copy of insurance cards if available)

Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.

- Remicade® is indicated for **Rheumatoid Arthritis**, in combination with methotrexate for moderately to severely active RA. Dose in conjunction with methotrexate, 3 mg/kg induction & then every 8 weeks. Some patients may benefit from increasing the dose up to 10 mg/kg or treating as often as every 4 weeks.
- Indicated for **Ankylosing Spondylitis**: Dose of 5 mg/kg induction & then every 6 weeks.
- Indicated for **Psoriatic Arthritis**: Dose of Psoriatic Arthritis & Plaque Psoriasis of 5 mg/kg induction & then every 8 weeks.

If patient is switching biological therapies, then MD must specify wash-out period prior to starting Remicade® as specified of _____ weeks. Last known biological therapy: _____ and last date received: _____. (Include copy of last Remicade® infusion record if available and currently on therapy)

Other as requested: _____

Pre-Screening: (TB and Hepatitis screening results must be available prior to start of therapy and within last 12 months.)

Required TB screening results: PPD or QuantiFERON Gold Test.

(* If screening results are positive or indeterminate, then a negative CXR result is required.)

Required Hepatitis screening to include: Hepatitis B Surface Antigen results.

**Product information suggests that patients who have stopped treatment for an extended period are at higher risk for hypersensitivity reactions. MD should evaluate premedication and consider antibody testing prior to restart of therapy.*

** Warnings/Precautions: **Serious Infections:** Patient should not have an active ongoing infection, signs or symptoms of malignancy, or invasive fungal infection. Do not initiate Remicade® (infliximab) therapy in patients with **moderate to severe Congestive Heart Failure**. **Remicade® (infliximab) at doses of >5 mg/kg should not be administer to patients with moderate to severe heart failure.** Patient with mild CHF currently receiving Remicade® (infliximab) should be closely monitored. Therapy should be discontinued in patients who develop new or worsening symptoms of heart failure. Evaluation of immunizations should be completed prior to and live vaccines should not be given before or concurrently with Remicade®. See full prescribing information.

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.